Cure8 research brief
The study links NAD+ precursor (NMN) supplementation to changes in TGF-β–associated gene programs, intestinal immune signatures, and the gut microbiome in mouse colitis models — pathways relevant to fibrosis and inflammation in IBD.
Researchers (NAD+/TGF-β/microbiome), translational scientists, and clinicians interested in IBD pathogenesis and preventive research
The paper reports that NMN altered TGF-β–associated transcriptional responses in cultured fibroblasts and in several mouse models, including DSS colitis and colitis-associated cancer models.
NMN was associated with increased expression of regeneration-associated genes, reduced fibrosis- and immune-related pathways in a prophylactic colitis model, shifts in gut bacterial communities, and long-term changes in colonic immune transcriptional signatures (including TGF-β and IgA-related pathways).
The authors did not find a change in tumor number in the cancer model but did observe transcriptional pathway alterations within tumors. These findings come from mouse and cellular models and describe associations between NMN supplementation, transcriptional changes, and microbiome shifts rather than demonstrated clinical benefits in people with IBD.
Findings are from mouse and cell models (preclinical). The paper reports transcriptional and microbiome associations, not clinical outcomes in humans; further translational and clinical research would be required.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study describes a new plant-derived nanoparticle (EBDEVs) that reduced inflammation and improved colon health in a mouse model of ulcerative colitis and altered the gut microbiota — early evidence that may guide...
FUT2 connects genetics, mucosal sugars, and the gut microbiome — pathways that could help explain why some people with IBD have different microbiomes or disease risk. If validated in trials, FUT2-targeted or...
This study reports a new colon-targeted delivery system for unconjugated bilirubin that reduced inflammation and improved mucosal healing in a mouse model of ulcerative colitis; it could inform future drug-development...
